whatpeptidestostack
← Compound library
TB-500
A short fragment of thymosin beta-4. Almost all outcome data are animal or laboratory, and the one human randomized trial used the full parent peptide, not the fragment.
The basics
| Human protocol on record | None published |
|---|---|
| Animal or laboratory figures | 2 |
| Published records retrieved | 38 |
| Registered trials | 11 |
| Certificate of analysis | Published by the partner |
| Regulatory status | Research-grade material, no approved human use |
1. The protocol on record
Hard disclaimer. Figures below are transcribed from a published study or an approved label exactly as the source states them. They record what researchers administered in a trial population, not instructions for any person, and none of it is adjusted to you. Most compounds here have no approved human use. Do not act on any of it without a licensed prescriber who knows your history.
Amounts and schedules, human record
No published human protocol exists for TB-500 in the cited record. No amount, frequency or schedule can be given here without inventing it, and this page does not invent figures.
Animal and laboratory models (not human figures)
| Phase or model | Amount | Frequency | Timing | Route | Duration | Source |
|---|---|---|---|---|---|---|
| Rat Achilles tendon transection and repair model | 60 µg/kg/day | per day | not stated | intraperitoneal | four weeks postoperatively | source |
| Equine doping-control detection study | 10mg of N-acetylated LKKTETQ | single dose | not stated | not stated | single dose | source |
Half-life and why the schedule looks like that
No measured half-life value is stated for TB-500 anywhere in the cited record. What the record does state: - A study of in vitro metabolism models for peptide doping agents, which included TB-500, states that detection of peptide hormone misuse is difficult because of their short half-life in plasma and rapid elimination. No numeric half-life is given (PMID: 25469748). - A dosing frequency without a half-life appears in the one animal efficacy study in the record: rats received TB-500 at 60 µg/kg/day intraperitoneally for four weeks after Achilles tendon repair. The abstract states the daily frequency but no half-life, clearance value, or duration-of-action figure (PMID: 42542926). - On clea
Handling and storage
- Lyophilised storage: Not stated in the cited record. - Storage after reconstitution: Not stated in the cited record. - Temperature: Not stated in the cited record. - Light: Not stated in the cited record. - Stability duration: Not stated in the cited record. One study in the record notes that TB-500, like other peptides, tends to adsorb to surfaces, and that recovery from laboratory glassware and plasticware varies with the consumable; this was an analytical-measurement finding, not storage guidance for any person (PMID: 28887173).
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Open the interactive builder for reconstitution maths and a calendar →
2. Safety and harm reduction
Reported adverse effects
No adverse effects are reported in the cited record for TB-500. That is an absence of published reporting, not evidence of safety.
Cautions stated in the literature
- TB-500 is an unapproved compound sold through a gray market operating largely outside regulatory oversight; rigorous human safety data are scarce, and there is potential for serious harm to patients (PMID: 41966639).
- Emerging peptide supplements including TB-500 are often perceived as low risk despite the absence of efficacy or safety data; human data are heterogeneous and reveal modest improvements at best, and significant heterogeneity exists in dosing and route of administration (PMID: 42578445).
- TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports (PMID: 41476424).
- TB-500 is classified as a doping agent under World Anti-Doping Agency regulations (PMID: 24906629).
- Non-approved peptides show promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation (PMID: 42021992).
- Most regenerative peptide therapies, including TB-500, remain unapproved by the U.S. Food and Drug Administration, and clinical evidence in humans is limited (PMID: 42635865).
- The biological effects of TB-500 itself have not been documented; one metabolism study suggests the wound-healing activity previously attributed to TB-500 may come from its metabolite Ac-LKKTE rather than the parent form (PMID: 38382158).
Stop and get help
- A severe or worsening reaction of any kind after administration.
- Signs of an allergic reaction, such as rash, itching, swelling of the face or throat, wheezing, or difficulty breathing.
- Signs of injection-site infection, such as spreading redness, warmth, swelling, pain, pus, or fever.
- Any unexpected symptom that persists or worsens.
Pairings
Co-administered
BPC-157 and TB-500
The pairing behind the informal wolverine nickname. Peptara Labs already publishes a page on this pair, so this is a short router card, not a full brief.
Open the pairing brief →Mentioned together
CJC-1295 and TB-500
Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.
Open the pairing brief →Co-administered
GHK-Cu and TB-500
Two peptides discussed for wound healing. One early human pilot put both in the same multi-ingredient formula, which is not the same as testing the pair.
Open the pairing brief →Mentioned together
Ipamorelin and TB-500
Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.
Open the pairing brief →TB-500 at Peptara Labs
Open the TB-500 pageRead the third-party certificate of analysis before anything else. Research-grade material, research use only.